Continuous versus intermittent β-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials.
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Rationale Optimization of β-lactam antibiotic dosing for critically ill patients is an intervention that may improve outcomes in severe sepsis. Objectives In this individual patient data meta-analysis of critically ill patients with severe sepsis, we aimed to compare clinical outcomes of those treated with continuous versus intermittent infusion of β-lactam antibiotics. Methods We identified relevant randomized controlled trials comparing continuous versus intermittent infusion of β-lactam antibiotics in critically ill patients with severe sepsis. We assessed the quality of the studies according to four criteria. We combined individual patient data from studies and assessed data integrity for common baseline demographics and study endpoints, including hospital mortality censored at 30 days and clinical cure. We then determined the pooled estimates of effect and investigated factors associated with hospital mortality in multivariable analysis. Measurements and main results We identified three randomized controlled trials in which researchers recruited a total of 632 patients with severe sepsis. The two groups were well balanced in terms of age, sex, and illness severity. The rates of hospital mortality and clinical cure for the continuous versus intermittent infusion groups were 19.6% versus 26.3% (relative risk, 0.74; 95% confidence interval, 0.56-1.00; P = 0.045) and 55.4% versus 46.3% (relative risk, 1.20; 95% confidence interval, 1.03-1.40; P = 0.021), respectively. In a m…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The desirable effects of empiric antiviral therapy are unknown, and as for other antimicrobial agents there is a risk of undesirable effects (165).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [165]
In the citing paper
“Two meta-analyses reported similar results supporting reduced short-term mortality (RR 0.70; 95% CI 0.57–0.87) with prolonged infusion of beta-lactams [232, 233].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [232]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Classification and Regression Trees.
Gordon, A. D., Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1984) · Biometrics · doi:10.2307/2530946 · Cited by 23,522
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
Cochrane Handbook for Systematic Reviews of Interventions
Tarsilla, M. (2010) · Journal of MultiDisciplinary Evaluation · doi:10.56645/jmde.v6i14.284 · Cited by 5,178
Cited by
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
“A recent individual patient data metaanalysis of randomized controlled trials comparing continuous versus intermittent infusion of β-lactam antibiotics in critically ill patients with severe sepsis demonstrated an independent protective effect of continuous therapy after adjustment for other correlatesof outcome [140].”
BackgroundSelf-citationSurviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Self-citationSurviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Self-citationAcute respiratory distress syndrome
Matthay, M. A., Zemans, R. L., Zimmerman, G. A., Arabi, Y. M., Beitler, J. R., Mercat, A., Herridge, M., Randolph, A. G., & Calfee, C. S. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0069-0 · Cited by 2,387
Guilhaumou, R., Benaboud, S., Bennis, Y., Dahyot-Fizelier, C., Dailly, E., Gandia, P., Goutelle, S., Lefeuvre, S., Mongardon, N., Roger, C., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2378-9 · Cited by 543
Advances in Antimicrobial Microneedle Patches for Combating Infections
Jamaledin, R., Yiu, C. K. Y., Zare, E. N., Niu, L., Vecchione, R., Chen, G., Gu, Z., Tay, F. R., & Makvandi, P. (2020) · Advanced Materials · doi:10.1002/adma.202002129 · Cited by 461
Hawkey, P. M., Warren, R. E., Livermore, D. M., McNulty, C. A. M., Enoch, D. A., Otter, J. A., & Wilson, A. P. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky027 · Cited by 334
Vardakas, K. Z., Voulgaris, G. L., Maliaros, A., Samonis, G., & Falagas, M. E. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30615-1 · Cited by 327
Surviving sepsis campaign: research priorities for sepsis and septic shock
Coopersmith, C. M., De Backer, D., Deutschman, C. S., Ferrer, R., Lat, I., Machado, F. R., Martin, G. S., Martin-Loeches, I., Nunnally, M. E., Antonelli, M., et al. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5175-z · Cited by 281
Kollef, M. H., Torres, A., Shorr, A. F., Martin-Loeches, I., & Micek, S. T. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000004783 · Cited by 217
Hagel, S., Bach, F., Brenner, T., Bracht, H., Brinkmann, A., Annecke, T., Hohn, A., Weigand, M., Michels, G., Kluge, S., et al. (2022) · Intensive Care Medicine · doi:10.1007/s00134-021-06609-6 · Cited by 182
“One approach to optimize exposure to β-lactam antibiotics is administration by prolonged (continuous or extended) infusion [8].”
BackgroundSelf-citationAbdul-Aziz, M. H., Hammond, N. E., Brett, S. J., Cotta, M. O., De Waele, J. J., Devaux, A., Di Tanna, G. L., Dulhunty, J. M., Elkady, H., Eriksson, L., et al. (2024) · JAMA · doi:10.1001/jama.2024.9803 · Cited by 180
Self-citationRawson, T. M., Gowers, S. A. N., Freeman, D. M. E., Wilson, R. C., Sharma, S., Gilchrist, M., MacGowan, A., Lovering, A., Bayliss, M., Kyriakides, M., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30131-1 · Cited by 180
Dulhunty, J. M., Brett, S. J., De Waele, J. J., Rajbhandari, D., Billot, L., Cotta, M. O., Davis, J. S., Finfer, S., Hammond, N. E., Knowles, S., et al. (2024) · JAMA · doi:10.1001/jama.2024.9779 · Cited by 171
Self-citationKollef, M. H., Bassetti, M., Francois, B., Burnham, J., Dimopoulos, G., Garnacho-Montero, J., Lipman, J., Luyt, C.-E., Nicolau, D. P., Postma, M. J., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4682-7 · Cited by 141
Self-citationS3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge
Deutsche Sepsis Gesellschaft e., V., Brunkhorst, F. M., Weigand, M. A., Pletz, M. W., Gastmeier, P., Lemmen, S., Meier‐Hellmann, A., Ragaller, M., Weyland, A., Marx, G., et al. (2020) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-020-00685-0 · Cited by 148
Rhodes, N. J., Liu, J., O’Donnell, J. N., Dulhunty, J. M., Abdul-Aziz, M. H., Berko, P. Y., Nadler, B., Lipman, J., & Roberts, J. A. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002836 · Cited by 130
“More recently, Roberts et al (2) conducted an individual patient data meta-analysis in 632 patients with severe sepsis.”
BackgroundSelf-citationSurviving Sepsis Campaign: Research Priorities for Sepsis and Septic Shock
Coopersmith, C. M., Backer, D. D., Deutschman, C. S., Ferrer, R., Lat, I., Machado, F. R., Martin, G. S., Martín‐Loeches, I., Nunnally, M., Antonelli, M. M., et al. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003225 · Cited by 128
Understanding and Managing Sepsis in Patients With Cancer in the Era of Antimicrobial Resistance
Gudiol, C., Albasanz‐Puig, A., Cuervo, G., & Carratalà, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.636547 · Cited by 132
Monti, G., Bradić, N., Marzaroli, M., Konkayev, A. K., Fominskiy, E. V., Kotani, Y., Likhvantsev, V. V., Momesso, E., Владимирович, Н. П., Lobreglio, R., et al. (2023) · JAMA · doi:10.1001/jama.2023.10598 · Cited by 134
Self-citationAn approach to antibiotic treatment in patients with sepsis
Martínez, M. L., Plata-Menchaca, E. P., Ruiz‐Rodríguez, J. C., & Ferrer, R. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.01.47 · Cited by 135
“The higher efficacy of betalactam antibiotics for targeting MDR microorganisms have been observed with prolonged infusions (127,137-140).”
BackgroundNeurotoxic Concentration of Piperacillin during Continuous Infusion in Critically Ill Patients
Quinton, M.-C., Bodeau, S., Kontar, L., Zerbib, Y., Maizel, J., Slama, M., Masmoudi, K., Lemaire‐Hurtel, A., & Bennis, Y. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00654-17 · Cited by 104
Kühn, D., Metz, C., Seiler, F., Wehrfritz, H., Roth, S., Alqudrah, M., Becker, A. P., Bracht, H., Wagenpfeil, S., Hoffmann, M., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03397-1 · Cited by 112
Pueyo, J. M., López, J. B., Soriano, À., Mondejar, P. L., Marco, F., Cantón, R., Bou, G., del Castillo, J. M. G., Garrido, E. M., Perea, J. R. A., et al. (2018) · PubMed Central · Cited by 102
Hartman, S. J. F., Brüggemann, R. J. M., Orriëns, L. B., Dia, N., Schreuder, M. F., & de Wildt, S. N. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00813-w · Cited by 111
Koulenti, D., Song, A., Ellingboe, A., Abdul-Aziz, M. H., Harris, P. N. A., Gavey, E., & Lipman, J. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.10.011 · Cited by 101
Self-citationKarvouniaris, M., Brotis, A. G., Tsiakos, K., Palli, E., & Koulenti, D. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s326456 · Cited by 105
“At present, there is only preliminary evidence for the benefit of administering continuous or prolonged over intermittent antibiotic infusion for the treatment of VM,(150) while this practice has been studied for the management of sepsis.(151,152) The prolonged, over 4 hours, meropenem infusion of 2g TDS in neurocriti…”
BackgroundRichter, D., Frey, O. R., Röhr, A. C., Roberts, J. A., Koeberer, A., Fuchs, T., Papadimas, N., Heinzel‐Gutenbrunner, M., Brenner, T., Lichtenstern, C., et al. (2019) · Infection · doi:10.1007/s15010-019-01352-z · Cited by 106
“[18] with remarkably low heterogeneity (I2 = 0 for hospital and ICU mortality) including 632 patients strikingly demonstrated significantly lower 30-day hospital mortality using CI of β-lactams.”
BackgroundSelf-citationDiagnostic and medical needs for therapeutic drug monitoring of antibiotics
Mabilat, C., Gros, M.-F., Nicolau, D. P., Mouton, J. W., Textoris, J., Roberts, J. A., Cotta, M. O., van Belkum, A., & Caniaux, I. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03769-8 · Cited by 100
Self-citationAn update on adverse drug reactions related to β-lactam antibiotics
Vardakas, K. Z., Kalimeris, G. D., Triarides, N. A., & Falagas, M. E. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1462334 · Cited by 94
Limitations of Antibiotic MIC-Based PK-PD Metrics: Looking Back to Move Forward
Landersdorfer, C. B., & Nation, R. L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.770518 · Cited by 101
Dalhoff, K., Abele‐Horn, M., Andreas, S., Deja, M., Ewig, S., Gastmeier, P., Gatermann, S. G., Gerlach, H., Grabein, B., Heußel, C. P., et al. (2018) · Pneumologie · doi:10.1055/s-0043-121734 · Cited by 97
Optimizing Antimicrobial Drug Dosing in Critically Ill Patients
Póvoa, P. M. S. R., Moniz, P., Gonçalves-Pereira, J., & Coelho, L. (2021) · Microorganisms · doi:10.3390/microorganisms9071401 · Cited by 91
“A meta-analysis of the individual data [210] of these three RCT pointed to a small, although significant, clinical benefit of continuous infusion, hospital mortality (19.”
Bellos, I., Karageorgiou, V., Pergialiotis, V., & Perrea, D. N. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.03.019 · Cited by 78
Society for Maternal-Fetal Medicine Consult Series #67: Maternal sepsis
Shields, A. D., Plante, L. A., Pacheco, L. D., & Louis, J. M. (2023) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2023.05.019 · Cited by 92
Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis
Shabaan, A. E., Nour, I., Eldegla, H., Nasef, N., Shouman, B., & Abdel‐Hady, H. (2016) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001445 · Cited by 77
Udy, A. A., Roberts, J. A., Lipman, J., & Blot, S. I. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.019 · Cited by 83
Self-citationGuidelines for Antibiotic Prescription in Intensive Care Unit
Guleria, R., Mohan, A., Kulkarni, A. P., Madan, K., & Hadda, V. (2019) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23101 · Cited by 94
Loeuille, G., D’Huart, É., Vigneron, J., Nisse, Y.-E., Beiler, B., Polo, C., Ayari, G., Sacrez, M., Demoré, B., & Charmillon, A. (2022) · Antibiotics · doi:10.3390/antibiotics11040458 · Cited by 75
“aeruginosa) to improve the clinical cure rate [3,4].”
BackgroundMinichmayr, I. K., Roberts, J. A., Frey, O. R., Roehr, A. C., Kloft, C., & Brinkmann, A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx526 · Cited by 75
Self-citationHanberg, P., Öbrink‐Hansen, K., Thorsted, A., Bue, M., Tøttrup, M., Friberg, L. E., Hardlei, T. F., Søballé, K., & Gjedsted, J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02390-17 · Cited by 70
“have been able to show a decreased hospital mortality in a recently published meta-analysis of individual patient data from randomized trials (31).”
BackgroundModifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance
Tamma, P. D., Beisken, S., Bergman, Y., Posch, A. E., Avdic, E., Sharara, S. L., Cosgrove, S. E., & Simner, P. J. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1306 · Cited by 72
Ehmann, L., Zoller, M., Minichmayr, I. K., Scharf, C., Huisinga, W., Zander, J., & Kloft, C. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.06.016 · Cited by 67
Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory
Grupper, M., Kuti, J. L., & Nicolau, D. P. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00022-16 · Cited by 72
Right Dose, Right Now: Customized Drug Dosing in the Critically Ill
Roberts, J. A., Kumar, A., & Lipman, J. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002210 · Cited by 70
Self-citationAntibiotic stewardship in the ICU: time to shift into overdrive
Mokrani, D., Chommeloux, J., Pineton de Chambrun, M., Hékimian, G., & Luyt, C.-E. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01134-9 · Cited by 56
“Whereas survival seems improved when continuous or prolonged beta-lactam infusion are used as compared to short-time infusion [133, 134], use of TDM during beta-lactam treatment does not seem to improve survival: indeed, a randomized-controlled trial evaluating the usefulness of TDM, as compared to no TDM, in patients…”
BackgroundCojutti, P. G., Sartor, A., Righi, E., Scarparo, C., Bassetti, M., & Pea, F. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00794-17 · Cited by 61
Ram, R., Halavy, Y., Amit, O., Paran, Y., Katchman, E. A., Yachini, B., Kor, S., Avivi, I. M., & Ben‐Ami, R. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy258 · Cited by 65
Gatti, M., & Pea, F. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1901574 · Cited by 65
Lanckohr, C., & Bracht, H. (2022) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000967 · Cited by 75
Liebchen, U., Paal, M., Scharf, C., Schroeder, I., Grabein, B., Zander, J., Siebers, C., & Zöller, M. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.08.027 · Cited by 66
Kalın, G., Alp, E., Chouaikhi, A., & Roger, C. (2023) · Microorganisms · doi:10.3390/microorganisms11102575 · Cited by 66
“Furthermore, the continuous administration of BL such as piperacillin/tazobactam and meropenem showed a reduction in clinical failures compared to an intermittent administration [121,122].”
BackgroundMaraolo, A. E., Cascella, M., Corcione, S., Cuomo, A., Nappa, S., Borgia, G., Rosa, F. G. D., & Gentile, I. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1367666 · Cited by 69
Optimizing the Use of Beta-Lactam Antibiotics in Clinical Practice: A Test of Time
Tilanus, A., & Drusano, G. L. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad305 · Cited by 67
Individualising Therapy to Minimize Bacterial Multidrug Resistance
Heffernan, A. J., Sime, F. B., Lipman, J., & Roberts, J. A. (2018) · Drugs · doi:10.1007/s40265-018-0891-9 · Cited by 63
Self-citationKondo, Y., Ota, K., Imura, H., Hara, N., & Shime, N. (2020) · Journal of Intensive Care · doi:10.1186/s40560-020-00490-z · Cited by 58
Antibiotics in Necrotizing Soft Tissue Infections
Urbina, T., Razazi, K., Ourghanlian, C., Woerther, P., Chosidow, O., Lepeule, R., & de Prost, N. (2021) · Antibiotics · doi:10.3390/antibiotics10091104 · Cited by 57
“021) in the continuous infusion group than in the intermittent infusion group in severe patients [75].”
BackgroundBenítez-Cano, A., Luque, S., Sorlí, L., Carazo, J., Ramos, I., Campillo, N., Curull, V., Sánchez‐Font, A., Vilaplana, C., Horcajada, J. P., et al. (2020) · Critical Care · doi:10.1186/s13054-020-2763-4 · Cited by 55
International survey of antibiotic dosing and monitoring in adult intensive care units
Williams, P. G., Tabah, A., Cotta, M. O., Sandaradura, I., Kanji, S., Scheetz, M. H., Imani, S., Elhadi, M. K., Luque, S., Schellack, N., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04527-1 · Cited by 56
“We found a significant shift toward beta-lactam EI use, which aligns with contemporary evidence, guideline recommendations and is associated with a short-term mortality benefit [16, 18, 30, 31].”
BackgroundSelf-citationLee, Y. R., Miller, P. D., Alzghari, S. K., Blanco, D. D., Hager, J. D., & Kuntz, K. S. (2017) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-017-0439-5 · Cited by 59
“The researchers did conclude that CI did not offer significant benefits for patients receiving RRT, as drug concentrations remained higher among this population regardless of administration strategy [43].”
BackgroundMethodInfluentialResistance Trends and Treatment Options in Gram-Negative Ventilator-Associated Pneumonia
Rhodes, N. J., Cruce, C. E., O’Donnell, J. N., Wunderink, R. G., & Hauser, A. R. (2018) · Current Infectious Disease Reports · doi:10.1007/s11908-018-0609-x · Cited by 59
Use of meropenem in treating carbapenem-resistant Enterobacteriaceae infections
Pascale, R., Giannella, M., Bartoletti, M., Viale, P., & Pea, F. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2019.1673731 · Cited by 48
Outpatient parenteral antimicrobial therapy and antibiotic stewardship: opponents or teammates?
Steffens, E., Quintens, C., Derdelinckx, I., Peetermans, W. E., Eldere, J. V., Spriet, I., & Schuermans, A. (2018) · Infection · doi:10.1007/s15010-018-1250-1 · Cited by 51
“As well in ICU as in non-ICU patients, PI of betalactams had no inferior effect on clinical success, adverse events and mortality [17, 48, 49].”
Lipman, J., Brett, S. J., Waele, J. J. D., Cotta, M. O., Davis, J. S., Finfer, S. R., Glass, P., Knowles, S., McGuinness, S., Myburgh, J., et al. (2019) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)00582-3 · Cited by 47
Self-citationNaik, B. I., Roger, C., Ikeda, K., Todorovic, M. S., Wallis, S. C., Lipman, J., & Roberts, J. A. (2017) · British Journal of Anaesthesia · doi:10.1093/bja/aex026 · Cited by 46
Self-citationPopulation pharmacokinetics of continuous infusion of piperacillin in critically ill patients
Dhaese, S. A. M., Roberts, J. A., Carlier, M., Verstraete, A., Stove, V. V., & Waele, J. J. D. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.12.015 · Cited by 48
Self-citationon behalf of the TARGET Study Group, Hagel, S., Fiedler, S., Höhn, A., Brinkmann, A., Frey, O. R., Hoyer, H., Schlattmann, P., Kiehntopf, M., Roberts, J. A., et al. (2019) · Trials · doi:10.1186/s13063-019-3437-x · Cited by 51
Self-citationAugmented Renal Clearance: What Have We Known and What Will We Do?
Luo, Y., Wang, Y., Ma, Y., Wang, P., Zhong, J. Q., & Chu, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.723731 · Cited by 44
“Further, pharmacokinetic/ pharmacodynamic (PK/PD) studies have shown that continuous infusion can also increase the probability of target attainment (Roberts et al., 2016; Barrasa et al., 2020).”
BackgroundBartoletti, M., Giannella, M., Lewis, R. E., Caraceni, P., Tedeschi, S., Paul, M., Schramm, C., Bruns, T., Merli, M., Cobos-Trigueros, N., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz032 · Cited by 45
“Previous randomized studies in different patient populations have demonstrated significant improvements in clinical outcome and survival in patients who received β-lactams or carbapenems by extended vs intermittent bolus infusion [15, 16, 25].”
BackgroundResultWilliams, P. G., Cotta, M. O., & Roberts, J. A. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1693498 · Cited by 46
Self-citationRoger, C. (2024) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2023.12.007 · Cited by 57
“[ 74 ] The most recent RCT that compared outcomes be-tween continuous and intermittent infusions of meropenem in a cohort of 607 critically ill patients found no significant difference in terms of all-cause mortality and the emergence of pandrug-or extensively drug-resistant bacteria at day 28.”
Masich, A. M., Heavner, M. S., Gonzales, J. P., & Claeys, K. C. (2018) · Current Infectious Disease Reports · doi:10.1007/s11908-018-0613-1 · Cited by 45
Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants
Tang, B., Wu, Y., Kou, C., Qi, Y., Qi, H., Xu, H.-Y., Leroux, S., Huang, X., Zhou, Y., Zheng, Y., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02336-18 · Cited by 42
Challenges and research priorities to progress the impact of antimicrobial stewardship
Bassetti, M., Giacobbe, D. R., Vena, A., & Brink, A. J. (2019) · Drugs in Context · doi:10.7573/dic.212600 · Cited by 45
Heffernan, A. J., Lim, S. M. S., Lipman, J., & Roberts, J. A. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100970 · Cited by 48
Self-citationAbdulla, A., Ewoldt, T. M. J., Purmer, I. M., Muller, A. E., Gommers, D. A. M. P. J., Endeman, H., & Koch, B. C. P. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1879049 · Cited by 44
“Recent meta-analyses have shown an association between extended infusion of β-lactams and lower mortality rates in critically ill patients with severe sepsis [70,71].”
BackgroundCojutti, P. G., Lazzarotto, D., Candoni, A., Dubbini, M. V., Zannier, M. E., Fanin, R., & Pea, F. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa267 · Cited by 40
Sepsis in Burns—Lessons Learnt from Developments in the Management of Septic Shock
Boehm, D., & Menke, H. (2021) · Medicina · doi:10.3390/medicina58010026 · Cited by 47
Abdul-Aziz, M. H., Portunato, F., & Roberts, J. A. (2020) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000681 · Cited by 38
“aeruginosa and Stenotrophomonas maltophilia) [44].”
Self-citationBiomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review
Sanz-Codina, M., & Zeitlinger, M. A. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01102-1 · Cited by 50
“Ultimately, inflammation and AUC area under the plasma concentration–time curve, Cmax maximum plasma drug concentration, G+/G− Gram positive/negative, MIC minimum inhibitory concentration, PB protein binding, PK/PD pharmacokinetics/pharmacodynamics, T>MIC time above MIC, t½ elimination halflife, Vd volume of distribut…”
BackgroundInfluentialКirov, М. Y., Владимирович, К. В., Николаевич, П. Д., Щеголев, А. В., Babaev, M. A., Belotserkovskiy, B. Z., Bykov, A. O., Gritsan, A. I., Кулабухов, В. В., Kulikov, A. V., et al. (2023) · Annals of critical care · doi:10.21320/1818-474x-2023-4-7-42 · Cited by 44
Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies
Stohs, E. J., Abbas, A., & Freifeld, A. G. (2024) · Transplant Infectious Disease · doi:10.1111/tid.14236 · Cited by 40
“39,40 43 Limited, single-center studies exist, 44–47 and a prospective, multicenter superiority clinical trial examining extended infusion of beta-lactams for FN is proposed.”
BackgroundFawaz, S., Barton, S., & Nabhani‐Gebara, S. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05149-6 · Cited by 45
Luo, G., Zhang, J., Sun, Y., Wang, Y., Wang, H., Cheng, B., Shu, Q., & Fang, X. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00598-3 · Cited by 46
Petersson, J., Giske, C. G., & Eliasson, E. (2016) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.12808 · Cited by 36
Identification of key genes in sepsis by WGCNA
Gao, X., Zhou, X., Jia, M.-W., Wang, X.-Z., & Liu, D. (2023) · Preventive Medicine · doi:10.1016/j.ypmed.2023.107540 · Cited by 38
Population Pharmacokinetics and Dosing Optimization of Ceftazidime in Infants
Shi, Z.-R., Chen, X., Tian, L., Wang, Y., Zhang, G.-Y., Dong, L., Jirasomprasert, T., Jacqz-Aigrain, É., & Zhao, W. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02486-17 · Cited by 36
Key Components for Antibiotic Dose Optimization of Sepsis in Neonates and Infants
van Donge, T., Bielicki, J. A., van den Anker, J. N., & Pfister, M. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00325 · Cited by 44
Mashni, O. K., Nazer, L. H., & Lê, J. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018790573 · Cited by 34
Carrié, C., Bentejac, M., Cottenceau, V., Masson, F., Petit, L., Cochard, J.-F., & Sztark, F. (2017) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2017.06.006 · Cited by 44
Rizk, N., Kanafani, Z. A., Tabaja, H., & Kanj, S. S. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1348894 · Cited by 36
“In addition, a meta-analysis of 632 critically ill patients with severe sepsis compared clinical outcomes of those treated with CI versus intermittent infusion of beta-lactam antibiotics [64].”
Dhaese, S. A. M., Heffernan, A. J., Liu, D. C., Abdul-Aziz, M. H., Stove, V. V., Tam, V. H., Lipman, J., Roberts, J. A., & Waele, J. J. D. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00919-6 · Cited by 32
Self-citationClinical features and outcome of septic shock in dogs: 37 Cases (2008‐2015)
Summers, A. M., Vezzi, N. K., Gravelyn, T., Culler, C. A., & Guillaumin, J. (2020) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/vec.13038 · Cited by 48
Verhaeghe, J., Dhaese, S. A. M., Corte, T. D., Mijnsbrugge, D. V., Aardema, H., Zijlstra, J. G., Verstraete, A., Stove, V. V., Colin, P. J., Ongenae, F., et al. (2022) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-022-01970-y · Cited by 34
“This decision is based on early studies indicating that individualized dosing may decrease mortality in ICU patients [3, 8, 9].”
BackgroundRoberts, J. A., Croom, K., & Adomakoh, N. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2184347 · Cited by 34
“One analysis included only RCTs [20] while the other two included both RCTs and non-randomized studies [22,25].”
BackgroundMethodResultInfluentialSelf-citationA three-level model for therapeutic drug monitoring of antimicrobials at the site of infection
Brasier, N., Ates, H. C., Sempionatto, J. R., Cotta, M. O., Widmer, A. F., Eckstein, J., Goldhahn, J., Roberts, J. A., Gao, W. F., & Dincer, C. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00215-3 · Cited by 35
Self-citationSime, F. B., Hahn, U., Warner, M. S., Tiong, I. S., Roberts, M. S., Lipman, J., Peake, S., & Roberts, J. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00311-17 · Cited by 33
Self-citationLeegwater, E., Kraaijenbrink, B. V. C., Moes, D. J. A. R., Purmer, I. M., & Wilms, E. B. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa067 · Cited by 34
Pharmakokinetik und Pharmakodynamik von Antibiotika in der Intensivmedizin
Sörgel, F., Höhl, R., Glaser, R., Stelzer, C., Munz, M., Vormittag, M., Kinzig, M., Bulitta, J. B., Landersdorfer, C. B., Junger, A., et al. (2016) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-016-0185-5 · Cited by 33
Metadata
- Authors
- Roberts, J. A., Abdul-Aziz, M.-H., Davis, J. S., Dulhunty, J. M., Cotta, M. O., Myburgh, J., Bellomo, R., & Lipman, J.
- Affiliations
- The University of Queensland (AU)
- International Islamic University Malaysia (MY)
- John Hunter Hospital (AU)
- Redcliffe Hospital (AU)
- The George Institute for Global Health (GB)
- Austin Hospital (AU)
- Department of Intensive Care Medicine and
- Corresponding author
- Roberts, Jason A.
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-09
- Volume
- 194
- Issue
- 6
- Pages
- 681-691
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2298261704
- Cited by
- 379
- References
- 46
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 45 · 2023: 51 · 2022: 37 · 2021: 44 · 2020: 43 · 2019: 38 · 2018: 38 · 2017: 39 · 2016: 15
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Health and Medical Research Council of Australia (APP1048652)
- Australian National Health and Medical Research Council (APP1099452)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Keywords
- severe sepsis, beta-lactam antibiotics, continuous infusion, intermittent infusion, antibiotic dosing, in-hospital mortality, clinical cure, critically ill patients, APACHE II score, renal replacement therapy, non-fermenting Gram-negative bacilli
- MeSH terms
- Aged, Anti-Bacterial Agents, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Proportional Hazards Models, Randomized Controlled Trials as Topic, Sepsis, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.